LAUSR

Limited data is available on the transition from subcutaneous to intravenous prostacyclin in precapillary pulmonary hypertension. We performed a retrospective analysis of all patients who were switched from subcutaneous to intravenous treprostinil with an implantable infusion pump. We included 85 consecutive, clinically stable patients (mean age 66 years, range 16 - 85), who had been treated with subcutaneous treprostinil for mean 9 months (range 1 - 78) before pump implantation. An interdisciplinary expert panel defined standards for this procedure before the first implantation. As the first patient experienced a significant hypotensive episode indicating treprostinil overdose postoperatively, the time span to stop subcutaneous treprostinil was reduced to 60 minutes for all following patients. No events associated with the switch from subcutaneous to intravenous treprostinil were observed during postoperative hospital stay in 84 (98,8%) patients. Taking into account a likely depot-effect of subcutaneous treprostinil patients can safely be switched to the intravenous route by the implantation of an infusion pump.